TrialJAMA oncology2017

Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.

Karim Chamie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.